Zacks Investment Research on MSN
Omeros gets FDA approval for YARTEMLEA as first therapy for TA-TMA
Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem ...
The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...
Summary • Omeros Corporation’s stock jumped 72.1% to $15.06 following FDA approval of Yartemlea, its therapy for TA-TMA.• Yartemlea is the first therapy targeting hematopoietic stem cell ...
Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® ...
(RTTNews) - Omeros Corp. (OMER), a clinical-stage biopharmaceutical company focused on complement-mediated diseases, oncology, and addictive disorders, today announced its financial results for the ...
Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...
In the retina, age-related macular degeneration (AMD) affects the complex of photoreceptors, retinal pigment epithelium (RPE), Bruch’s membrane (BM) and the choriocapillaris, the innermost layer of ...
Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
Stroke is associated with vascular events that follow the initial insult and involve the activation of several blood-borne cascades including coagulation, contact/kinin, and complement cascade. There ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback